Utilization of Intraocular Dexamethasone Implant 0.7mg in a Large Retina Practice.

Abstract

Purpose : Intraocular injection of Dexamethasone Implant 0.7mg (Ozurdex) is used for treatment for a variety of ophthalmic diseases. A retrospective observational clinical study was performed to determine the different diagnoses being treated with Ozurdex at a large retina practice.

Methods : Drawing on internal data from a large retinal specialty practice between 2015 and 2022, we identified the number of patients undergoing intraocular Ozurdex treatment. This group comprised 165 individuals with an average age of 72. The patients were then categorized by diagnosis, including 6 diagnoses of three or more patients and 2 diagnoses with 2 or less patients.

Results : A total of 165 patients receiving Ozurdex were identified. Data collected showed that 41.2% (68 patients) were being treated for diabetic macular edema, 24.8% (41 patients) were for central retinal vein occlusion with macular edema,17.0% (28 patients) were for branch retinal vein occlusion with macular edema, 8.5% (14 patients) were for pseudophakic cystoid macular edema, 3.6% (6 patients) were for macular/retinal edema, 3.0% (5 patients) were for uveitis, 1.2 % (2 patients) were for diabetic retinopathy, and 0.6 % (1 patients) were for neovascular macular degeneration.

Conclusions : The study found patients had 8 unique diagnoses that were treated with Ozurdex. Diabetic macular edema constituted the largest proportion of the treated patient population at 41.2%. Categories with 4 patients or less in them constituted 1.8% of the patient population. Future studies could examine the effects of Ozurdex on intraocular pressure as well as which diagnosis is most improved with Ozurdex.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.